Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Andrew N J TuttJudy E GarberBella KaufmanGiuseppe VialeDebora FumagalliPriya RastogiRichard D GelberEvandro de AzambujaAnitra FieldingJudith BalmañaSusan M DomchekKaren A GelmonSimon J HollingsworthLarissa A KordeBarbro LinderholmHanna BandosElżbieta SenkusJennifer M SugaZhimin ShaoAndrew W PippasZbigniew NoweckiTomasz HuzarskiPatricia A GanzPeter C LucasNigel BakerSibylle LoiblRobin McConnellMartine PiccartRita SchmutzlerGuenther G StegerJoseph P CostantinoAmal ArahmaniNorman WolmarkEleanor McFaddenVassiliki KarantzaSunil R LakhaniGreg YothersChristine CampbellCharles E Geyernull nullPublished in: The New England journal of medicine (2021)
Among patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants, adjuvant olaparib after completion of local treatment and neoadjuvant or adjuvant chemotherapy was associated with significantly longer survival free of invasive or distant disease than was placebo. Olaparib had limited effects on global patient-reported quality of life. (Funded by the National Cancer Institute and AstraZeneca; OlympiA ClinicalTrials.gov number, NCT02032823.).